NCT05727800View on ClinicalTrials.gov

A Phase 1, First-in-human Study of VX-668

PHASE1CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

February 8, 2023

Primary Completion Date

September 12, 2023

Study Completion Date

February 13, 2024

Conditions
Alpha-1 Antitrypsin Deficiency
Interventions
DRUG

VX-668

Suspension for oral administration.

DRUG

Placebo

Suspension for oral administration.

Trial Locations (5)

32610

University of Florida, Gainesville

32803

Central Florida Pulmonary Group, P.A., Orlando

66219

ICON Lenexa, Lenexa

84124

ICON Salt Lake City, Salt Lake City

85283

Celerion - Tempe, Tempe

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY